These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1963033)

  • 1. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
    Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of specific antibodies to herpes simplex virus type 2 as revealed by an enzyme-linked immunoassay and western blot analysis.
    Spiezia KV; Dille BJ; Mushahwar IK; Kifle L; Okasinski GF
    Adv Exp Med Biol; 1990; 278():231-42. PubMed ID: 1963039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
    Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
    Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
    Ishizaka ST; Mishkin EM
    Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
    Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
    J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
    Bernstein DI; Miller RL; Harrison CJ
    J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.
    McDermott MR; Graham FL; Hanke T; Johnson DC
    Virology; 1989 Mar; 169(1):244-7. PubMed ID: 2538036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.
    Bröker M; Abel KJ; Köhler R; Hilfenhaus J; Amann E
    Med Microbiol Immunol; 1990; 179(3):145-59. PubMed ID: 2169577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for vaccines for herpes simplex viruses.
    Berman PW
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):226-30. PubMed ID: 2828443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.